|
Current issue
Archive
Videos
Articles in press
About the journal
Supplements
Editorial board
Reviewers
Abstracting and indexing
Subscription
Contact
Instructions for authors
Publication charge
Ethical standards and procedures
Editorial System
Submit your Manuscript
|
3/2024
vol. 126 Review article
Changes in the organ of vision in neurofibromatosis type 1 in the developmental age
Mirosława Grałek
1
,
Katarzyna Piasecka
1
,
Katarzyna Wasyliszyn-Sieroszewska
1
,
Anna Niwald
1
KLINIKA OCZNA 2024, 126, 3: 119-123
Online publish date: 2024/10/09
Get citation
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
1. Kang E, Yoo, Lee BH. Neurofibromatosis type 1: points to be considered by general pediatricians. Clin Exp Pediatr 2021; 64, 4: 149-156. 2.
Prutenau DP, Oltenau DE, Cosnarovici R i wsp. Genetic predisposition in pediatric oncology. Med Pharm Rep 2020; 93: 323-334. 3.
Campen CJ, Gutmann D. Optic pathway gliomas in neurophibromatosis type 1. J Child Neurol 2018; 33: 73-81. 4.
Kofla-Dłubacz A, Andrzej Stawarski A, Pytrus T, Gil J. Fakomatozy – znaczenie badań genetycznych dla personalizacji postępowania klinicznego (część 1). Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory 2021; 6: 512-519. 5.
Peduto C, Zanobio M, Nigro V i wsp. Neurofibromatosis Type 1: Pediatric Aspects and Review of Genotype-Phenotype Correlations. Cancers (Basel) 2023; 15: 1217. 6.
Duarte JV, Ribeiro MJ, Violante IR, Cunha G i wsp. Multivariate pattern analysis reveals subtle brain anomalies relevant to the cognitive phenotype in neurofibromatosis type 1. Hum Brain Mapp 2014; 35: 89-106. 7.
Czajkowki G, Kałużny J, Jatczak-Gaca A, Wysocki M. Patogeneza i najczęstsze objawy nerwiakowłókniakowtości typu 1. Klin Oczna 2009; 111: 378-383. 8.
Czajkowski G, Kalużny J, Jatczak-Gaca A, Wysocki M. Nerwiakowłokniakowatość typu 1. w obserwacjach własnych. Klin Oczna 2010; 112: 45-48. 9.
Kehrer- Sawatzki H, Coopper DN. Challenges in the diagnosis of neurofibromatosis type 1 (NF1) in young children facilitated by means of revised diagnostic criteria including genetic testing for pathogenic NF1 gene variants. Hum Genet 2022; 141: 177-191. 10.
Tarasiuk J, Kułakowska A, Drozdowski W. Współwystępowanie nerwiakowłókniakowatości typu 1. i glejaka skrzyżowania nerwów wzrokowych – opis przypadku. Aktualn Neurol 2010; 10: 55- 59. 11.
Campen CJ, Gutmann DH. Optic Pathway Gliomas in Neurofibromatosis Type 1. J Child Neurol 2018; 33: 73-81. 12.
De Blank PMK, Fisher MJ, Liu GT i wsp. Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment, Indications, and Biomarkers of Vision. J Neuroophthalmol 2017; 37 Suppl 1: 523-532. 13.
Freret ME, Gutmann DH. Understanding Vision Loss from Optic Pathway Glioma in Neurofibromatosis Type 1. J Neurosci Res 2019; 97: 45-56. 14.
Kresak JL, Walsh M. Neurofibromatosis: A Review of NF1, NF2, and Schwannomatosis. J Pediatr Genet 2016; 5: 98-104. 15.
Adams EG, Stewart KMA, Borges OA, Darling T. Multiple, unilateral Lisch Nodules in the Absence of other Manifestations Neurofibromatosiss Type 1. Case Rep Ophthalmol Med 2011; 2011: 854784. 16.
Boley S, Sloan JL, Pemoy A, Stewart DR. A Quantitative Assessment on the Burden and Distribution of Lisch Nosules in adults with Neurofibromatoma Type 1. Invest Vis Sci Ophthalmol 2009; 50: 5035-5043. 17.
Peduto C, Zanobio M, Nigro V i wsp. Neurofibromatosis Type 1: Pediatric Aspects and Review of Genotype–Phenotype Correlations. Cancers (Basel) 2023; 15: 1217. 18.
Ferraz-Filho JR, da Rocha AJ, Munitz MP i wsp. Unidentified bright objects in neurofibromatosis type 1: conventional MRI in the follow-up and correlation of microstructural lesions on diffusion tensor images. Eur J Paediatr 2012; 16: 42-47. 19.
Liu S, Qi D, Meng X, Yu T. Neovascular glaucoma in a pediatric patient with neurofibromatosis type 1: a case report. BMC Ophthalmol 2020; 20: 168. 20.
Karwacki MW, Wysocki M, Perek-Polnik M, Jatczak-Gaca A. Coordinate medical care for children with neurofibromatosis type 1 and related RASopathies in Poland. Arch Med Arch Med Sci 2021; 17: 1221-1231. 21.
Salech M, Dib A, Beaini S i wsp. Neurofibromatosis type 1 system-based manifestations and treatments: a review. Neurol Sci 2023; 44: 1931-1947.
|
|
POLSKI
